Published in BMC Cardiovasc Disord on April 28, 2014
Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr (2015) 0.82
Association of six CpG-SNPs in the inflammation-related genes with coronary heart disease. Hum Genomics (2016) 0.81
CD36 binds oxidized low density lipoprotein (LDL) in a mechanism dependent upon fatty acid binding. J Biol Chem (2015) 0.80
Soluble cluster of differentiation 36 concentrations are not associated with cardiovascular risk factors in middle-aged subjects. Biomed Rep (2016) 0.75
New circulating biomarkers for predicting cardiovascular death in healthy population. J Cell Mol Med (2015) 0.75
CD36 in chronic kidney disease: novel insights and therapeutic opportunities. Nat Rev Nephrol (2017) 0.75
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens (1999) 11.00
Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr (2007) 4.63
Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation (2001) 3.03
Influence of obesity on immune function. J Am Diet Assoc (1999) 2.42
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood (2001) 2.40
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation (1998) 2.32
Inflammation, oxidative stress, and obesity. Int J Mol Sci (2011) 2.05
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2001) 1.89
CD36 and macrophages in atherosclerosis. Cardiovasc Res (2007) 1.85
Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest (2008) 1.77
The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes (2004) 1.62
CD36: implications in cardiovascular disease. Int J Biochem Cell Biol (2007) 1.62
Platelet and leptin in obese adolescents. J Pediatr (Rio J) (2008) 1.53
Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol (2000) 1.51
Foam cells in atherosclerosis. Clin Chim Acta (2013) 1.39
Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation (2006) 1.38
Comparison of numbers of circulating blood monocytes in men grouped by body mass index (<25, 25 to <30, > or =30). Am J Cardiol (2002) 1.38
Nuts and novel biomarkers of cardiovascular disease. Am J Clin Nutr (2009) 1.35
Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36. Cleve Clin J Med (2009) 1.18
Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans. Arterioscler Thromb Vasc Biol (2009) 1.17
Obesity-associated oxidative stress: strategies finalized to improve redox state. Int J Mol Sci (2013) 1.15
Body fat and circulating leukocytes in children. Int J Obes (Lond) (2006) 1.14
The relationships of adiponectin with insulin and lipids are strengthened with increasing adiposity. J Clin Endocrinol Metab (2005) 1.13
Platelet counts and platelet activation markers in obese subjects. Mediators Inflamm (2008) 1.10
Interleukin-6 production in human subcutaneous abdominal adipose tissue: the effect of exercise. J Physiol (2002) 1.08
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med (2011) 1.07
CD36 and TLR interactions in inflammation and phagocytosis: implications for malaria. J Immunol (2009) 1.05
Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. J Clin Endocrinol Metab (2010) 1.01
Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care (2007) 0.98
The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. J Thromb Haemost (2011) 0.97
Obesity-hypertension: an ongoing pandemic. Int J Clin Pract (2007) 0.95
Systemic inflammation in childhood obesity: circulating inflammatory mediators and activated CD14++ monocytes. Diabetologia (2012) 0.94
The origin of circulating CD36 in type 2 diabetes. Nutr Diabetes (2013) 0.94
CD36: a multi-modal target for acute stroke therapy. J Neurochem (2009) 0.92
CD36 as a therapeutic target for endothelial dysfunction in stroke. Curr Pharm Des (2012) 0.90
Pathophysiology and biochemistry of cardiovascular disease. Curr Opin Genet Dev (2004) 0.89
Circulating soluble CD36 is associated with glucose metabolism and interleukin-6 in glucose-intolerant men. Diab Vasc Dis Res (2009) 0.89
In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes (2002) 0.88
Hypoxia enhances lipid uptake in macrophages: role of the scavenger receptors Lox1, SRA, and CD36. Atherosclerosis (2013) 0.88
Adipokines, oxidized low-density lipoprotein, and C-reactive protein levels in lean, overweight, and obese portuguese patients with type 2 diabetes. ISRN Obes (2013) 0.85
Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6. Blood (1991) 0.84
Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free Radic Biol Med (2012) 0.83
Soluble CD36- a marker of the (pathophysiological) role of CD36 in the metabolic syndrome? Arch Physiol Biochem (2011) 0.83
Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. Indian J Med Res (2010) 0.82
Molecular imaging in atherosclerosis. Eur J Nucl Med Mol Imaging (2010) 0.81
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. J Viral Hepat (2012) 0.81
Circulating soluble CD36 is a novel marker of liver injury in subjects with altered glucose tolerance. J Nutr Biochem (2008) 0.81
Prevalence of cardiovascular risk factors in Taiwanese healthcare workers. Ind Health (2009) 0.81
Development and application of a nonradioactive binding assay of oxidized low-density lipoprotein to macrophage scavenger receptors. J Lipid Res (2013) 0.80
Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease. Diabetol Metab Syndr (2013) 0.79
Oxidized low-density lipoprotein and ankle-brachial pressure index in patients with clinically evident peripheral arterial disease. Clinics (Sao Paulo) (2010) 0.78
[Oxidized LDL and anti-oxidized LDL antibodies according uric acid levels in overweight women]. Arch Cardiol Mex (2011) 0.78
Body fat distribution and its association with hypertension in a sample of Mexican children. J Investig Med (2011) 0.93
Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico. Genet Test Mol Biomarkers (2012) 0.86
A functional Ser(413)/Ser(413) PAI-2 polymorphism is associated with susceptibility and damage index score in systemic lupus erythematosus. Clin Appl Thromb Hemost (2008) 0.85
Adenovirus-36 seropositivity and its relation with obesity and metabolic profile in children. Int J Endocrinol (2013) 0.85
Maternal admixture and population structure in Mexican-Mestizos based on mtDNA haplogroups. Am J Phys Anthropol (2013) 0.82
Increased expression of the prolactin receptor is associated with malignant laryngeal tumors. Exp Ther Med (2012) 0.82
Relationship of metabolic syndrome and its components with -844 G/A and HindIII C/G PAI-1 gene polymorphisms in Mexican children. BMC Pediatr (2012) 0.81
Polymorphisms of alcohol metabolizing enzymes in indigenous Mexican population: unusual high frequency of CYP2E1*c2 allele. Alcohol Clin Exp Res (2009) 0.80
Cardiovascular risk evaluated by C-reactive protein levels in diabetic and obese Mexican subjects. Circ J (2008) 0.79
FCGR3A V(176) polymorphism for systemic lupus erythematosus susceptibility in Mexican population. Rheumatol Int (2010) 0.78
High expression of prolactin receptor is associated with cell survival in cervical cancer cells. Cancer Cell Int (2013) 0.77
Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children. J Pediatr (Rio J) (2013) 0.77
Prehypertension in a Mexican population: influence of age, gender, and body fat. Clin Exp Hypertens (2012) 0.77
PAI-1 mRNA expression and plasma level in rheumatoid arthritis: relationship with 4G/5G PAI-1 polymorphism. Rheumatol Int (2011) 0.77
CD36 haplotypes are associated with lipid profile in normal-weight subjects. Lipids Health Dis (2013) 0.77
Establishment of a cut-point value of serum TNF-alpha levels in the metabolic syndrome. J Clin Lab Anal (2009) 0.76
Gut Microbiota and Metabolic Endotoxemia in Young Obese Mexican Subjects. Obes Facts (2016) 0.76
Significant associations between C-reactive protein levels, body adiposity distribution and peripheral blood cells in school-age children. Invest Clin (2016) 0.75
MIF and TNFα serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study. Immunopharmacol Immunotoxicol (2015) 0.75